[1]Patent:US2008/146515,2008,A1.Locationinpatent:Page/Pagecolumn4
[1]Patent:WO2017/71813,2017,A1.Locationinpatent:Page/Pagecolumn12
[2]Patent:CN103694230,2016,B.Locationinpatent:Paragraph0072;0073
[3]Patent:CN109553609,2019,A.Locationinpatent:Paragraph0090;0100;0101;0102;0105;0115;0116;0117
[4]Patent:WO2009/35969,2009,A1.Locationinpatent:Page/Pagecolumn80
[5]Patent:WO2016/16852,2016,A1.Locationinpatent:Page/Pagecolumn9;10
[6]Patent:CN108191841,2018,A.Locationinpatent:Paragraph0042;0047
[1]Patent:WO2009/35969,2009,A1.Locationinpatent:Page/Pagecolumn79-80
[1]Patent:WO2017/71813,2017,A1.Locationinpatent:Page/Pagecolumn14
[2]JournaloftheAmericanChemicalSociety,2017,vol.139,p.10693-10701
[3]Patent:CN109180662,2019,A.Locationinpatent:Page/Pagecolumn8-11
[4]Patent:CN109553609,2019,A.Locationinpatent:Paragraph0090;0103;0104;0105;0118;0119
[5]Patent:CN107459500,2017,A.Locationinpatent:Paragraph0022;0023
[6]Patent:CN108191841,2018,A.Locationinpatent:Paragraph0042;0048;0054;0060
[7]Patent:WO2009/35969,2009,A1.Locationinpatent:Page/Pagecolumn81
[8]Patent:US2010/99883,2010,A1.Locationinpatent:Page/Pagecolumn39
[9]Patent:US2010/99883,2010,A1.Locationinpatent:Page/Pagecolumn43
[10]Patent:WO2016/83790,2016,A1.Locationinpatent:Page/Pagecolumn5;13
[11]Patent:CN103694230,2016,B.Locationinpatent:Paragraph0070;0072;0074;0075
[12]Patent:CN107286143,2017,A.Locationinpatent:Paragraph0061;0062
[13]Patent:US2016/228375,2016,A1.Locationinpatent:Paragraph0105;0106
[14]Patent:CN109456315,2019,A.Locationinpatent:Paragraph0022
[15]Patent:CN110698468,2020,A.Locationinpatent:Paragraph0024;0051-0057;0062-0065
Title: Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action.
Journal: Chemico-biological interactions 20171101
Title: Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.
Journal: Chemico-biological interactions 20171101
Title: Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model.
Journal: Chemico-biological interactions 20161025
Title: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Journal: Clinical pharmacokinetics 20150701
Title: Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.
Journal: Toxicologic pathology 20150101
Title: Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
Journal: Chemico-biological interactions 20141205
Title: Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Journal: Chemico-biological interactions 20140925
Title: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.
Journal: Expert opinion on drug metabolism & toxicology 20130601
Title: Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Journal: Current medical research and opinion 20120701
Title: Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Journal: Current medical research and opinion 20120701
Title: C-Aryl 5a-carba-β-d-glucopyranosides as novel sodium glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Journal: Bioorganic & medicinal chemistry 20120701
Title: A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials.
Journal: Annals of medicine 20120601
Title: Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Journal: Diabetes, obesity & metabolism 20120601
Title: Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Journal: Diabetes care 20120601
Title: [New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].
Journal: Orvosi hetilap 20120506
Title: Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models.
Journal: PloS one 20120101
Title: Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Journal: Diabetes, obesity & metabolism 20110701
Title: A new approach to glucose control in type 2 diabetes: the role of kidney sodium-glucose co-transporter 2 inhibition.
Journal: Postgraduate medicine 20110701
Title: New diabetes drugs go beyond insulin to flush out excess sugar.
Journal: Nature medicine 20110601
Title: Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
Journal: Journal of medicinal chemistry 20110113
Title: Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Journal: Journal of medicinal chemistry 20100909
Title: Liang Y, et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One. 2012;7(2):e30555.
